Comparative Pharmacology
Head-to-head clinical analysis: BACI RX versus BACIGUENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACI RX versus BACIGUENT.
BACI-RX vs BACIGUENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.
None Documented
None Documented
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 mL/min.
Terminal elimination half-life approximately 2.5–3.5 hours in adults with normal renal function; prolonged in renal impairment (up to 20–30 hours in anuria)
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Primarily renal excretion of unchanged drug via glomerular filtration and tubular secretion; >90% of absorbed dose recovered in urine within 24 hours; biliary/fecal elimination minimal (<2%)
Category C
Category C
Topical Antibiotic
Topical Antibiotic